治疗中心距离对HPV阴性头颈癌患者生存的影响
该研究基于全州人群的回顾性队列,纳入936例HPV阴性头颈鳞状细胞癌患者,计算其家庭住址至放疗、手术和化疗中心的欧几里得距离,并用多变量Cox比例风险模型分析距离四分位数与5年死亡风险的关系。结果显示,与第一四分位数相比,第四四分位数患者放疗的死亡风险比为0.59(95%CI 0.42-0.83;p=0.002),手术为0.47(95%CI 0.30-0.75;p=0.001),化疗为0.56(95%CI 0.35-0.91;p=0.020),即旅行距离更远的患者总生存改善。
要点
- 936例HPV阴性头颈鳞癌患者中,放疗、手术、化疗的中位旅行距离分别为10.2、11.1、10.9英里。
- 距离第四四分位数患者更可能居住在农村(p<0.001)并在学术医院接受治疗(p<0.001)。
- 校正后总生存随旅行距离增加而改善,第三和第四四分位数患者的改善仍显著。
核心结论
- 在该人群队列中,为治疗HPV阴性头颈鳞癌而旅行距离更远的患者总生存改善。
- 该分析提示,协调的多学科诊疗的获益可能超过旅行负担带来的障碍。
研究设计与样本
- 回顾性识别自全州人群研究中的HPV阴性头颈鳞癌患者,共936例,平均年龄60岁。
- 计算家庭住址至放疗、手术和化疗中心的欧几里得距离。
- 采用多变量Cox比例风险模型分析距离四分位数增加与5年死亡风险的关系。
主要发现
- 患者至放疗、手术、化疗中心的中位距离分别为10.2、11.1、10.9英里。
- 距离第四四分位数患者更可能居住在农村(p<0.001)并在学术医院接受治疗(p<0.001)。
- 校正后总生存随旅行距离增加而比例改善,第三和第四四分位数患者的改善仍显著。
- 与第一四分位数相比,第四四分位数患者放疗的死亡风险降低(HR 0.59,95%CI 0.42-0.83;p=0.002)。
- 与第一四分位数相比,第四四分位数患者手术的死亡风险降低(HR 0.47,95%CI 0.30-0.75;p=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In rural states, travel burden for complex cancer care required for head and neck squamous cell carcinoma (HNSCC) may affect patient survival, but its impact is unknown. METHODS: Patients with HPV-negative HNSCC were retrospectively identified from a statewide, population-based study. Euclidian distance from the home address to the treatment center was calculated for radiation therapy, surgery, and chemotherapy. Multivariable Cox proportional hazards models were used to examine the risk of 5-year mortality with increasing travel quartiles. RESULTS: There were 936 patients with HPV-negative HNSCC with a mean age of 60. Patients traveled a median distance of 10.2, 11.1, and 10.9 miles to receive radiation therapy, surgery, and chemotherapy, respectively. Patients in the fourth distance quartile were more likely to live in a rural location (p < 0.001) and receive treatment at an academic hospital (p < 0.001). Adjusted overall survival (OS) improved proportionally to distance traveled, with improved OS remaining significant for patients who traveled the furthest for care (third and fourth quartile by distance). Relative to patients in the first quartile, patients in the fourth had a reduced risk of mortality with radiation (HR 0.59, 95% CI 0.42-0.83; p = 0.002), surgery (HR 0.47, 95% CI 0.30-0.75; p = 0.001), and chemotherapy (HR 0.56, 95% CI 0.35-0.91; p = 0.020). CONCLUSION: For patients in this population-based cohort, those traveling greater distances for treatment of HPV-negative HNSCC had improved OS. This analysis suggests that the benefits of coordinated, multidisciplinary care may outweigh the barriers of travel burden for these patients.
引用
- Farquhar DR, Masood MM, Lenze NR, et al. Effect of distance of treatment center on survival for HPV-negative head and neck cancer patients. Head Neck. 2023. PMID: 37767817. doi:10.1002/hed.27522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。